FDA approves Bristol Myers and Karuna's schizophrenia drug, in milestone for psychiatry
The FDA on Thursday approved Bristol Myers Squibb’s new schizophrenia drug in one of the year’s most anticipated regulatory decisions.
The approval gives Bristol Myers …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.